News & Media

Press Releases

Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and Metabolic Diseases

Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and …

Download a PDF: EN or FR

Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

Amolyt Pharma 3 announces that it has completed a €67 million Series A financing round …

Download a PDF: EN or FR

Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company focused on rare endocrine and metabolic diseases

Announces a key addition to its leadership team and the structuring of its product portfolio in line with its ambition to become a leading global rare disease company …

Download a PDF: EN or FR

Presentations

  • All PRESENTATIONS
  • AZP-3813
  • AZP-3601
  • AZP-3404
All PRESENTATIONS
  • All PRESENTATIONS
  • AZP-3813
  • AZP-3601
  • AZP-3404
AZP-3601

Living With an “Invisible Disease”: A Qualitative Study With Patients With Hypoparathyroidism

AZP-3813

Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly. ENDO 2022 Presentation.

AZP-3813

Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly. ENDO 2022 Poster.

AZP-3813

AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor as a Potential New Treatment for Acromegaly

AZP-3601

Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States

AZP-3601

KOL Webinar on AZP-3601 Featuring John P. Bilezikian, M.D., Ph.D.

AZP-3601

Clinical Burden of Patients with Hypoparathyroidism in the United States: A Claims Data Analysis. ASMBR 2021.

AZP-3601

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Single and Multiple Administration of AZP-3601, a Novel Long-Acting PTH Analog, to Healthy Adults. ASMBR 2021.

AZP-3601

Safety, Tolerability and Pharmacodynamics of AZP-3601, a Novel Long-Acting PTH Analog, in Healthy Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. e-ECE 2021.

AZP-3601

cHP Natural History Study: ISPOR Poster

AZP-3601

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Upcoming events

Date: June 1, 2022

Date: June 10 – June 14, 2022 (Atlanta, Georgia)

Date: September 9 - 12, 2022 (Austin, TX)

Social Updates

TWITTER

Scroll to Top